Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient and post-discharge prophylaxis: a meta-analysis of randomized controlled trials
CONCLUSION: For non-critically ill patients, therapeutic dose prophylactic anticoagulation significantly reduced venous thromboembolism but increases major bleeding risk. Intermediate dose effectively lowered venous thromboembolism without raising major bleeding risk. The optimal dose and need for additional antiplatelet therapy in critically ill patients, as well as the necessity of prophylactic anticoagulation in outpatient and post-discharge patients, required further investigation and confirmation through rigorous evidence studies.PMID:38549227 | DOI:10.1097/JS9.0000000000001307
Source: Hand Surgery - Category: Surgery Authors: Jiahao Meng Hang Tang Yifan Xiao Weijie Liu Yumei Wu Yilin Xiong Shuguang Gao Source Type: research
More News: Bleeding | COVID-19 | Databases & Libraries | Men | Science | Study | Surgery | Thrombosis